PUBLICATION

Global Business Reports

AUTHORS

Razvan Isac, Ty Jeevaratnam

Québec Mining 2016 Pre-Release 2

April 21, 2016

Québec’s mining industry climate has changed considerably over the past three years in terms of legislative stability, commodity prices, and mineral diversification. With a new government in power and a new mining code finally implemented, investors’ confidence in the viability of this jurisdiction has been reinforced. Gold producers across the province have been ramping up efforts, and benefiting from the favorable CAD/USD exchange rates, while the industry’s iron ore segment has experienced a slowdown as a result of the global market conditions. Meanwhile, Québec has seen activity intensifying within its non-traditional mineral spectrum, with the advent of feasible projects in diamonds, apatite, and electric metals. All throughout, despite the industry’s ups and downs, Québec’s mature service sectors providers have continued to innovate, and expand their operations on a global scale, shaping the world’s mining scene. Amidst all the changes, after attending PDAC in Toronto, and spending several weeks in Val D’Or, Rouyn-Noranda, and Québec City, Global Business Reports is proud to showcase its mining research, one that we hope will continue to inspire the “moderate optimism” the market has been experiencing in recent months.

 

RELATED INTERVIEWS MORE INTERVIEWS

Tembo Power is developing hydropower projects across Africa with a focus on DRC.
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Robocon speaks with GBR about the outlook for its services in Peru.
"Our product innovation process involves gathering client feedback and submitting it to the factory, which determines which ideas to pursue based on economic considerations."

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED

SUBSCRIBE TO OUR NEWSLETTER